<DOC>
	<DOC>NCT00727727</DOC>
	<brief_summary>The objective of the Post Marketing Surveillance Study is to investigate the use of the non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy in patients with Morbus Parkinson. Neurologists in private practices in Germany should document the safety and course of the disease/change of parkinsonian symptoms during stabilisation on, or change over from other dopamine agonist treatment under routine conditions. Piribedil should be prescribed according to its marketing authorisation.</brief_summary>
	<brief_title>SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Piribedil</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<criteria>Male and female patients 18 years and older. Indication: Morbus Parkinson. Treatment with piribedil for the first time. Monotherapy with piribedil. Combination therapy with LDopa (from the beginning or secondary in combination with other antiparkinsonian drugs).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Piribedil (trade name: Clarium)</keyword>
	<keyword>non-ergot dopamine agonist</keyword>
	<keyword>Morbus Parkinson</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Post Marketing Surveillance</keyword>
</DOC>